ENTRADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 16.92K shares, a 39.79% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 10.10K shares, a 75.35% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 5.97K shares, a 94.91% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 3.11K shares, a 95.08% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 62.17K shares, a 83.54% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 377.67K shares, a 76.42% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 214.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 16.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 36.11K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 10.10K shares 10-Q · filed 2026-05-07 | 31.29K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 5.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 62.17K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 3.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 173.60K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 12.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 233.72K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 40.98K shares 10-Q · filed 2025-05-08 | 387.76K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 117.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 377.67K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 63.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 329.20K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 166.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 346.60K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 30.89K shares 10-Q · filed 2024-05-07 | 226.62K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 68.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 214.08K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 80.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2023-06-30 | 46.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | |
| 2023-03-31 | 18.34K shares 10-Q · filed 2023-05-10 | |
| 2022-09-30 | 26.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | |
| 2022-06-30 | 5.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | |
| 2022-03-31 | 24.89K shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |